Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Synovial Sarcoma: Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Synovial Sarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Synovial Sarcoma

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Gastric Cancer: Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Gastric Cancer

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Metastatic Melanoma: Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Metastatic Melanoma

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Solid Tumor: Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase III for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Solid Tumor

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Kidney Cancer (Renal Cell Cancer)....

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Kidney Cancer (Renal Cell Cancer)

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Renal Cell Carcinoma: Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Renal Cell Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Renal Cell Carcinoma

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Non-Small Cell Lung Cancer: Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Non-Small Cell Lung Cancer

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According...

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Gastroesophageal (GE) Junction Carcinomas

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma): Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)....

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma)

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Metastatic Renal Cell Carcinoma: Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Metastatic Renal Cell Carcinoma. According...

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Metastatic Renal Cell Carcinoma

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Dedifferentiated Liposarcoma: Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Dedifferentiated Liposarcoma

Data Insights

Sitravatinib malate by Bristol-Myers Squibb for Epithelial Ovarian Cancer: Likelihood of Approval

Sitravatinib malate is under clinical development by Bristol-Myers Squibb and currently in Phase II for Epithelial Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Sitravatinib Malate in Epithelial Ovarian Cancer